The Chemours Co has a consensus price target of $27.53, established from looking at the 57 latest analyst ratings. The last 3 analyst ratings were released from UBS, BMO Capital, and BMO Capital on March 5, 2024, March 1, 2024, and February 29, 2024. With an average price target of $19.67 between UBS, BMO Capital, and BMO Capital, there's an implied -23.48% downside for The Chemours Co from these 3 analyst ratings.
1calculated from analyst ratings published within the last 3 years
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
---|---|---|---|---|---|---|---|---|---|---|---|
03/05/2024 | CC | Buy Now | Chemours | $25.70 | -18.29% | UBS | Joshua Spector | $37 → $21 | Downgrade | Buy → Neutral | Get Alert |
03/01/2024 | CC | Buy Now | Chemours | $25.70 | -26.07% | BMO Capital | John McNulty | $45 → $19 | Downgrade | Outperform → Underperform | Get Alert |
02/29/2024 | CC | Buy Now | Chemours | $25.70 | -26.07% | BMO Capital | John McNulty | $45 → $19 | Downgrade | Outperform → Underperform | Get Alert |
12/01/2023 | CC | Buy Now | Chemours | $25.70 | 55.64% | RBC Capital | Arun Viswanathan | $28 → $40 | Upgrade | Sector Perform → Outperform | Get Alert |
11/07/2023 | CC | Buy Now | Chemours | $25.70 | 1.17% | JP Morgan | Jeffrey Zekauskas | $38 → $26 | Maintains | Neutral | Get Alert |
10/31/2023 | CC | Buy Now | Chemours | $25.70 | 16.73% | Goldman Sachs | Duffy Fischer | $35 → $30 | Maintains | Neutral | Get Alert |
10/30/2023 | CC | Buy Now | Chemours | $25.70 | 8.95% | RBC Capital | Arun Viswanathan | $30 → $28 | Maintains | Sector Perform | Get Alert |
10/30/2023 | CC | Buy Now | Chemours | $25.70 | 51.75% | BMO Capital | John McNulty | $45 → $39 | Maintains | Outperform | Get Alert |
10/30/2023 | CC | Buy Now | Chemours | $25.70 | 8.95% | Morgan Stanley | Vincent Andrews | $33 → $28 | Maintains | Equal-Weight | Get Alert |
10/30/2023 | CC | Buy Now | Chemours | $25.70 | 8.95% | Barclays | Michael Leithead | $31 → $28 | Maintains | Equal-Weight | Get Alert |
10/04/2023 | CC | Buy Now | Chemours | $25.70 | 20.62% | Barclays | Michael Leithead | $40 → $31 | Maintains | Equal-Weight | Get Alert |
08/02/2023 | CC | Buy Now | Chemours | $25.70 | 106.23% | BMO Capital | John McNulty | $64 → $53 | Maintains | Outperform | Get Alert |
08/01/2023 | CC | Buy Now | Chemours | $25.70 | 28.4% | Morgan Stanley | Vincent Andrews | $33 → $33 | Reiterates | Equal-Weight → Equal-Weight | Get Alert |
07/31/2023 | CC | Buy Now | Chemours | $25.70 | 55.64% | RBC Capital | Arun Viswanathan | $37 → $40 | Maintains | Sector Perform | Get Alert |
07/19/2023 | CC | Buy Now | Chemours | $25.70 | 28.4% | Morgan Stanley | Vincent Andrews | $33 → $33 | Reiterates | Equal-Weight → Equal-Weight | Get Alert |
07/11/2023 | CC | Buy Now | Chemours | $25.70 | 55.64% | Barclays | Michael Leithead | $38 → $40 | Maintains | Equal-Weight | Get Alert |
06/22/2023 | CC | Buy Now | Chemours | $25.70 | 43.97% | B of A Securities | Matthew DeYoe | $41 → $37 | Downgrade | Buy → Neutral | Get Alert |
06/13/2023 | CC | Buy Now | Chemours | $25.70 | 67.32% | UBS | Joshua Spector | $41 → $43 | Maintains | Buy | Get Alert |
06/09/2023 | CC | Buy Now | Chemours | $25.70 | 43.97% | RBC Capital | Arun Viswanathan | $36 → $37 | Maintains | Sector Perform | Get Alert |
The latest price target for Chemours (NYSE: CC) was reported by UBS on March 5, 2024. The analyst firm set a price target for $21.00 expecting CC to fall to within 12 months (a possible -18.29% downside). 24 analyst firms have reported ratings in the last year.
The latest analyst rating for Chemours (NYSE: CC) was provided by UBS, and Chemours downgraded their neutral rating.
The last upgrade for The Chemours Co happened on December 1, 2023 when RBC Capital raised their price target to $40. RBC Capital previously had a sector perform for The Chemours Co.
The last downgrade for The Chemours Co happened on March 5, 2024 when UBS changed their price target from $37 to $21 for The Chemours Co.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Chemours, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Chemours was filed on March 5, 2024 so you should expect the next rating to be made available sometime around March 5, 2025.
While ratings are subjective and will change, the latest Chemours (CC) rating was a downgraded with a price target of $37.00 to $21.00. The current price Chemours (CC) is trading at is $25.70, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.